zaltrap 25 mg/1 ml koncentrat za rastvor za infuziju
amicus pharma d.o.o. - aflibercept - koncentrat za rastvor za infuziju - 25 mg/1 ml - 8 ml koncentrata za rastvor za infuziju sadrži: 200 mg aflibercepta
zaltrap 25 mg/1 ml koncentrat za rastvor za infuziju
amicus pharma d.o.o. - aflibercept - koncentrat za rastvor za infuziju - 25 mg/1 ml - 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg aflibercepta
zaltrap
sanofi winthrop industrie - aflibercept - kolorektalne neoplazme - antineoplastična sredstva - liječenje metastaziranog kolorektalnog karcinoma (mcrc).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
eylea 40 mg/1 ml otopina za injekciju
bayer d.o.o. sarajevo - aflibercept - otopina za injekciju - 40 mg/1 ml - 1 ml otopine sadrži 40 mg aflibercepta
eylea
bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - Эйлеа indiciran za odrasle za liječenje:неоваскулярной (vlažna) senilne makularne degeneracije (amd), poremećaj vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr);vida zbog dijabetes pomagala макулярного edema (ДМО);vida zbog миопической хориоидальной неоваскуляризации (миопической ХНВ).
eylea 40 mg/1 ml otopina za injekciju
bayer d.o.o. sarajevo - aflibercept - otopina za injekciju - 40 mg/1 ml - 1 ml otopine sadrži 40 mg aflibercepta
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
beovu
novartis europharm limited - brolucizumab - mokro makularna degeneracija - ophthalmologicals - beovu prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd).
beovu 120 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - brolucizumab - rastvor za injekciju - 120 mg/1 ml - 1staklena bočica sadrži: 27,6 mg brolucizimaba u 0,23 ml rastvora